Natalizumab: Bench to bedside and beyond

JAMA Neurology

Volumn 70, Issue 2, 2013, Pages 172-182

  Rudick, Richard ^a   Polman, Chris ^b   Clifford, David ^c   Miller, David ^d   Steinman, Lawrence ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

ADD ON THERAPY; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY RESPONSE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; EXPANDED DISABILITY STATUS SCALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; JC VIRUS; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYOMAVIRUS INFECTION; POST HOC ANALYSIS; POSTMARKETING SURVEILLANCE; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT DURATION; UNITED STATES; VIRUS LOAD; VIRUS REACTIVATION;

EID: 84874041029     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.598     Document Type: Review

References (79)

1. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012; 18(2):143-152.
2. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov. 2005;4(6):510-518.
3. European Medicines Agency. Tysabri (natalizumab) authorisation details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000603/human-med-001119.jsp&jsenabled=true#authorisation. Accessed November 23, 2011.
4. US Food and Drug Administration. Natalizumab approval letter. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2004/125104-0000-ltr. pdf. Accessed November 17, 2011.
5. US Food and Drug Administration. Public health advisory: suspended marketing of Tysabri (natalizumab). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051761. htm. Accessed November 17, 2011.
6. European Commission approves inclusion of anti-JC virus antibody status as a PML risk factor in TYS labeling [news release]. Weston, Massachusetts, and Dublin, Ireland: Biogen Idec; June 22, 2011. http://www.biogenidec.com/press- release-details.aspx?ID=5981&ReqId=1576802. Accessed September 24, 2012.
7. US Food and Drug Administration. FDA drug safety communication: new risk factor for progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab). http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm. Accessed January 26, 2012.
8. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375-381.
9. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4):369-374.
10. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005; 353(4):362-368.
11. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272 (5258):60-66.
12. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76(2):301-314.
13. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 1989;59(6):1203-1211.
14. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990;60(4):577-584.
15. Rivers TM, Sprunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med. 1933;58(1):39-53.
16. Stamper HBJ Jr, Woodruff JJ. Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules. J Exp Med. 1976;144(3):828-833.
17. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356(6364):63-66.
18. Verbeek MM, Westphal JR, Ruiter DJ, de Waal RM. T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4/vascular cell adhesion molecule-1 interactions. J Immunol. 1995;154(11):5876-5884.
19. Yang XD, Michie SA, Tisch R, Karin N, Steinman L, McDevitt HO. A predominant role of integrin alpha 4 in the spontaneous development of autoimmune diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 1994;91(26):12604-12608.
20. Elan Corporation and Athena Neurosciences stockholders approve merger [news release]. Dublin, Ireland, and San Francisco, California: PR Newswire Europe Ltd; June27,1996.http://www.prnewswire.co.uk/news-releases/elan- corporation-and-athena-neurosciences-stockholders-approve-merger-156539975.html. Accessed September 24, 2012.
21. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999;52(5):1072-1074.
22. Elan and Biogen announce positive phase II results for Antegren (R) (natalizumab) in multiple sclerosis and Crohn's disease [news release]. Cambridge, Massachusetts, and Dublin, Ireland: PR Newswire; January 22, 2001. http://www.prnewswire.com/news-releases/elan-and-biogen-announce-positive-phase- ii-results-for-antegrenr-natalizumab-in-multiple-sclerosis-and-crohns-disease- 71075222.html. Accessed January 9, 2012.
23. Vollmer TL, Phillips JT, Goodman AD, et al. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler. 2004;10(5):511-520.
24. Goodman AD, Rossman H, Bar-Or A, et al; GLANCE Investigators. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806-812.
25. Tubridy N, Behan PO, Capildeo R, et al; The UK Antegren Study Group. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology. 1999;53(3):466-472.
26. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al; Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004;62(11):2038-2043.
27. Miller DH, Khan OA, Sheremata WA, et al; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15-23.
28. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988;111(pt 4):927-939.
29. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993;34(5):661-669.
30. Miller DH, Albert PS, Barkhof F, et al; US National MS Society Task Force. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol. 1996;39(1):6-16.
31. Schwid SR, Noseworthy JH. Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss. Neurology. 1999;53(3):444-445
32. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol. 2004;251(4):407-413.
33. Polman CH, O'Connor PW, Havrdová E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. NEngl J Med. 2006;354(9):899-910
34. Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923
35. Radue EW, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci. 2010;292(1-2):28-35
36. Weinstock-Guttman B, Galetta SL, Giovannoni G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol. 2011 259(5):898-905
37. Miller DH, Soon D, Fernando KT, et al; AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 68(17):1390-1401.
38. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68(16):1299-1304
39. Rudick RA, Miller D, Hass S, et al; AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007;62(4):335-346.
40. O'Connor P, Miller D, Riester K, et al; International Natalizumab Trial Group. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. MultScler 2005;11(5):568-572
41. Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011;68(4):464-468
42. Hutchinson M, Kappos L, Calabresi PA, et al; AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256(3):405-415.
43. Havrdová E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260.
44. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. MultScler. 2011;17(8):970-979.
45. Bates D, Bartholomé E. Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity. J Neurol Neurosurg Psychiatry. 2012;83(1):55-60.
46. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L; Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53(8):1698-1704
47. Calabresi PA, Giovannoni G, Confavreux C, et al; AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391-1403
48. Biogen Idec. About us: history. http://www.biogenidec.com/history.html. Accessed November 17, 2011
49. YousryTA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab forprogressive multifocal leukoencephalopathy. NEnglJMed. 2006; 354(9):924-933
50. Tysabri [package insert]. Cambridge, Massachusetts: Biogen Idec Inc; 2012.
51. Tysabri (natalizumab): summary of product characteristics. Electronic Medicines Compendium website. http://www.medicines.org.uk/emc/document.aspx? documentid=18447&docType=SPC. Accessed November 23,2011
52. Clifford DB, De LucaA, Simpson DM, ArendtG, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases [published correction appears in Lancet Neurol. 2010;9(5):463]. Lancet Neurol. 2010;9(4):438-446
53. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009;361(11):1081-1087
54. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20) 1870-1880.
55. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77 (11):1061-1067.
56. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76 (20):1697-1704
57. Iaffaldano P, D'Onghia M, Trojano M. Safety profile of Tysabri: international risk management plan. Neurol Sci. 2009;30(suppl 2):S159-S162
58. Fox R. Advances in the management of PML: focus on natalizumab. Cleve Clin J Med. 2011;78(suppl 2):S33-S37
59. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy: revisited. J Infect Dis. 2011;203(5):578-586.
60. Iaffaldano P, LuccheseG, TrojanoM. Treating multiple sclerosis with natalizumab Expert Rev Neurother 2011;11(12):1683-1692.
61. US Food and Drug Administration. FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm288471.htm. Accessed January 26, 2012
62. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303
63. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 76(22)1858-1865.
64. Borriello G, Prosperini L, Marinelli F, Fubelli F, Pozzilli C. Observations during an elective interruption of natalizumab treatment: a post-marketing study. MultScler 2011;17(3):372-375
65. Kaufman MD, Lee R, Norton HJ. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. MultScler. 2011;17(4):490-494.
66. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68(3):392-395
67. Krysko KM, O'Connor PW. The Toronto observational study of natalizumab in multiple sclerosis. Can J Neurol Sci. 2011;38(3):422-428.
68. Outteryck O, Ongagna JC, Zéphir H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010; 257(2):207-211
69. Mancardi GL, Tedeschi G, Amato MP, et al. Three years of experience: the Italian registry and safety data update. Neurol Sci. 2011;31(suppl 3):295-297
70. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009;16(3):420-423.
71. Belachew S, Phan-Ba R, Bartholomé E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy n relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(2):240-245.
72. Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol. 2010; 63(2):101-106
73. Holmén C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011 17(6)708-719
74. Natalizumab treatment of progressive multiple sclerosis (NAPMS). http://clinicaltrials.gov/ct2/show/NCT01077466. Accessed June 18, 2012
75. A clinical study of the efficacy of natalizumab on reducing disability progression in subjects with SPMS (ASCEND in SPMS). http://clinicaltrials.gov/ ct2/show/NCT01416181. Accessed June 18, 2012
76. Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol. 2009;13(1):67-71
77. Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab use n pediatric multiple sclerosis. Arch Neurol. 2008;65(12):1655-1658
78. Ghezzi A, Pozzilli C, Grimaldi LME, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75(10):912-917
79. Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. TherAdv Neurol Disord. 2010;3(5):293-299.